Pantoprazole Olikla (Pantoprazole Sodium Sesquihydrate)

Pantoprazole Olikla is a proton‑pump inhibitor that acts on gastric acid secretion pathways. It is used in several acid‑related gastrointestinal conditions:

• Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation.
• Erosive esophagitis: accelerates mucosal healing and reduces recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the disorder.

• Pantoprazole inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the parietal cell surface of the stomach lining. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity and allowing damaged mucosa to heal.

Pantoprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: increased intestinal gas.
• Constipation: infrequent bowel changes.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): rash, swelling, breathing difficulty.
• Clostridioides difficile infection: persistent watery diarrhea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Acute interstitial nephritis: kidney inflammation.
• Liver enzyme elevation: signs of hepatic stress.

When prescribing Pantoprazole Olikla, consider the following safety measures:

• Assess renal function: adjust use in severe impairment.
• Review concomitant medications: potential for altered absorption of drugs requiring acidic pH.
• Monitor long‑term users: watch for bone density loss and magnesium deficiency.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit evaluation.
• Elderly patients: start at the lowest effective dose and monitor for adverse effects.
• Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines. Awareness of the interaction potential helps maintain therapeutic effectiveness.

Major Interactions (Avoid)

• Ketoconazole or itraconazole: reduced antifungal absorption leading to treatment failure.
• Atazanavir: markedly decreased antiviral exposure.
• Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring more frequent coagulation monitoring.
• Digoxin: slight rise in serum levels, watch for toxicity signs.
• Methotrexate: elevated concentrations, especially at high doses.
• Iron supplements: decreased iron absorption, consider timing separation.